UPDATE 1-Teva Pharm eyes more acquisitions after buying Allergan's generics business

JERUSALEM, Aug 4 (Reuters) - Teva Pharmaceutical Industries

will remain in the hunt for more acquisitions after

completing a deal to buy Allergan's generics business

for $40.5 billion this week.

Read more